Drug

OPB-111077

As of the edition of 20 October 2026, OPB-111077 is a drug known only by a code name: in active development; acts on STAT3.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Active, 2017
Kind
Code name only
Registered trials
6, 1 stopped early
Disease areas
Cancer; Blood and lymph; Immune system

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Companies that need a new molecule because of this drug

1 company on route A because of this drug.

Companies on route A for this drug

In the product

1 company is on route A because of OPB-111077.

Target

GeneProteinUniProt
STAT3Signal transducer and activator of transcription 3P40763

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 15401
Phase 21000
All trials6

Who ran its trials

CompanyRoleYears
OtsukaLead sponsor of trials2012 to now
OtsukaLead sponsor of trials2013 to now